GASTER control® & GLP-1 Therapies
Supporting Patients Along Pharmacological Treatment Pathways
GLP-1 receptor agonists have become a central component in the management of overweight and obesity.
GASTER control® is designed to complement these therapies by providing a non-invasive, biomechanical approach supporting the perception of satiety and the regulation of food intake.
The Role of GLP-1 Therapies
A Major Advancement in Obesity Management
GLP-1–based treatments have demonstrated significant clinical benefits, including:
- reduction in appetite
- weight loss
- improvement in metabolic parameters
They are now widely integrated into treatment strategies across multiple patient profiles.
Clinical Challenges in Real-World Use
Despite their efficacy, several challenges are observed in clinical practice:
- variability in patient response
- gastrointestinal side effects in some patients
- treatment discontinuation or dose reduction
- weight regain after treatment interruption
- difficulty maintaining long-term behavioral changes
These factors highlight the importance of complementary approaches supporting patients throughout their treatment journey.
A Need for Complementary Non-Pharmacological Support
GLP-1 therapies primarily act through neuro-hormonal pathways.
However, the regulation of food intake also involves:
- mechanical signals (gastric distension)
- behavioral and perceptual factors
Supporting these dimensions may contribute to:
- improved patient engagement
- better integration of satiety cues
- stabilization of eating behaviors over time
The Contribution of GASTER control®
GASTER control® provides a non-invasive, external biomechanical approach designed to:
- support the perception of satiety during meals
- support the regulation of food intake
- contribute to behavioral stabilization phases
It acts on the mechanical component of satiety by applying controlled external abdominal compression.
This approach does not replace pharmacological action,
but may support patients in integrating satiety signals into daily eating behavior.
Clinical Positioning
GASTER control® may be considered in several contexts:
- during GLP-1 treatment, to support eating behavior regulation
- during dose reduction phases
- after treatment discontinuation
- in patients requiring additional non-pharmacological support
It is intended as a complementary tool, within structured care pathways.
A Complementary, Not Competitive Approach
GASTER control® is not intended to replace GLP-1–based therapies.
It is designed to complement them by addressing different physiological and behavioral dimensions of appetite regulation.
This combined perspective reflects a broader approach to obesity management, integrating:
- pharmacological treatment
- behavioral support
- non-invasive mechanical modulation
Clinical Perspective
The integration of pharmacological and non-pharmacological approaches represents an evolving paradigm in metabolic health.
GASTER control® contributes to this evolution by offering:
- a non-invasive support option
- compatibility with real-life use
- integration into multidisciplinary care
Ongoing Evaluation
The role of GASTER control® alongside GLP-1 therapies is currently being explored through:
- real-world observational data
- clinical use in multidisciplinary settings
- ongoing structured clinical development
Further studies are needed to better define its impact in combination strategies.
Summary
GASTER control® is designed to complement GLP-1 therapies by supporting the perception of satiety and the regulation of food intake through a non-invasive biomechanical approach.
It contributes to a broader, integrated strategy for long-term patient management.